4'-C-叠氮基胞嘧啶核苷2',3',5'-三异丁酸酯

别名 / 同义词: R1626、Ro 4588161、CS-1493、4'-C-Azidocytidine 2',3',5'-tris(2-methylpropanoate)、(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate)、isobutyric acid (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-4-isobutyryloxy-2-isobutyryloxymethyltetrahydrofuran-3-yl ester

4'-C-叠氮基胞嘧啶核苷2',3',5'-三异丁酸酯（CAS 690270-29-2）是晶世纪化学数据库收录的医药中间体。分子式为 C21H30N6O8，分子量为 494.49800 g/mol。又称 R1626、Ro 4588161、CS-1493。目前暂无供应商报价，可通过联系页询价。数据更新于 2026年8月21日。

CAS号: 690270-29-2
晶世纪编号: J-920170-9
分子式: C₂₁H₃₀N₆O₈
分子量: 494.49800 g/mol
分类: 医药中间体
更新时间: 2026/8/21

该化合物暂无报价。

获取报价

基础理化性质

精确质量	494.21300
其他信息	198.79000
LogP	1.72966
储存条件	2-8℃

活性 / 生物活性

描述	Balapiravir (R1626, Ro 4588161)是R1479(RG1479)的原药,是HCV的RNA聚合酶核苷类似物抑制剂。
相关类别	信号通路 >> 抗感染 >> HCV 研究领域 >> 感染
参考文献	[1]. Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450. [2]. Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31. [3]. Li F, et al. Chemical stability of 4'-azidocytidine and its prodrug balapiravir.Drug Dev Ind Pharm. 2010 Apr;36(4):413-20. [4]. kros PJ, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.Hepatology. 2008 Aug;48(2):385-97. [5]. Roberts SK, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.Hepatology. 2008 Aug;48(2):398-406. [6]. Chen YL, et al. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol. 2014 Feb;88(3):1740-1747.

常见问题